References
- Fishman AP. State of the art: Chronic cor pulmonale. Am Rev Respir Dis1976;114:775-94
- Rounds S, Hill NS. Pulmonary hypertensive diseases. Chest 1984;85:397-405
- Kessler R, Faller M, Fourgaut G, Mennecier B, Weitz enblum E. Predictive factors of hospitalization for acute exacerbation in a Series of 64 patients withchronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:158-64
- Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 1972;286:912-8
- Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981;36:752-8
- Staub NC. Site of hypoxic pulmonary vasoconstriction. Chest 1985;88:240S-245S
- Wright JL, Lawsom L, Pare PD, Hooper RO, Peretz DI, Nelems JM, et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. The effect of oxyger and exercise Am Rev Respir Dis 1983; 128:702-7
- Hale KA, Niewoehner DE, Cosio MG. Morphologic changes in the muscular pulmonary arteries: relationship to cigarette smoking, airway disease, andemphysema. Am Rev Respir Dis 1980;122:273-8
- Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease; a uinical trial Nocternal Oxygen Therapy Trial Group. Ann Intern Med 1980;93: 391-8
- Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981;1:681-6
- Vik-Mo H, Walde N, Jentoft H, Halvorsen FJ. Improved hemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long term oral prazocin therapy in chronic cor pulmonale. Eur Heart J 1985;6:1047-53
- Agostoni P, Doria E, Galli C, Tamborini G, Guazzi MD. Nifedipine reduces pulmonary pressure and vasodilator tone during short-but not long-termtreatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;139:120-5
- Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349:1365
- Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki F, et al. Effect of orally active prostacyclin analogue on survival of outpatients with primarypulmonary hypertension. J Am Coll Cardiol 1999;34: 1188-92
- Melian EB, Goa KL. Beraprost: a review of its pharmacology and therapeutic efficacy in treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002;62:107-33
- Vizza CD, Sciomer S, Morelli S, Lavalle C, Di Marzio P, Padovani D, et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 2001;86:661-5
- Dinh-Xuan AT, Higenbottam TW, Clelland CA, Pepke-Zaba J, Cremona G, Butt AY, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991;324:1539-47
- Kanazawa H, Okamoto T, Hirata K, Yoshikawa J. Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1235-8
- Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-80
- Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: The Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997;155:1278-82
- Criner GJ, Cordova FC, Furukawa S, Kuzma AM, Travaline JM, Leyenson V, et al. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:2018-27
- Yoshida M, Taguchi O, Gabazza EC, Kobayashi T, Yamakami T, Kobayashi H, et al. Combined inhalation of nitric oxide and oxygen in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;155:526-9
- Sajkov D, McEvoy RD, Cowie RJ, Bradley JA, Antic R, Morris RG, et al. Felodipine improves pulmonary hemodynamics in chronic obstructive pulmonarydisease. Chest 1993;103:1354-61
- Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984;70:657-62
- Tramarin R, Torbicki A, Merchandise B, Laaban JP, Morpurgo M. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructivepulmonary disease. A Europian multicentre study. Working group on Noninvasjre Fraluation of pulmonary artery pressure. European office of the world health orqanization, coperhageu Eur Heart J 1991;12:103-11
- ATS statement: guidelines for the six-minute walk test. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. Am J Respir Crit Care Med 2002 ;166(1):111-7
- Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92